Merck Slims R&D Spend, Homes In On Best Assets Like Lambrolizumab
This article was originally published in The Pink Sheet Daily
Merck advises that R&D spend for 2013 will be a lower than 2012 as it absorbs a hit from patent expirations of major products. Company stresses that it will prioritize drugs that have potential to shake up clinical practice, like lambrolizumab in oncology and MK-8931 in Alzheimer’s disease.
You may also be interested in...
Pfizer lowers overall growth guidance for emerging markets this year but remains bullish on prospects for growth as EMs become more like mature markets in reimbursement and overall health care policies. Merck meanwhile emphasized cost-cutting measures and Amgen sets its sights on Japan.
Phase I data for immune checkpoint molecules in melanoma from Bristol, Roche and Merck were a major highlight of the ASCO 2013 annual meeting. Considering potential application in many cancers regardless of genetic mutations, some analysts are predicting billions in future sales.
Company says it will not pursue regulatory filings for the adenosine-2a receptor antagonist because studies in moderate-to-severe and early-stage disease failed to show sufficient evidence of efficacy.